AHRENS, BIANCA,BAXI, SANGITA M.,BERGQVIST, SIMON PAUL,DOYONNAS, REGIS,DUFIELD, ROBERT LEE,ELLIOTT, MARK WILLIAM,FISHER, TIMOTHY SCOTT,JEROME, RICHARD MICHAEL,JONES, HEATHER LAURANCE,KAMPERSCHROER, CRI
申请号：
PE2013000404
公开号：
PE20131465A1
申请日:
2011.08.26
申请国别(地区):
PE
年份:
2014
代理人:
摘要：
It refers to IgG2 antibody molecules combined with a 4-1b B, including: (a) sec No. 29 h-cdr1, (b) sec No. 30 h-cdr2, (c) sec No. 31 h-cdr3, (d) sec No. 34 l-cdr1, (E) sec No. 35 l-cdr2, (f) sec No. 36 l-cdr3. These molecules have a region VH with SEC ID No: 43 and a region VL with SEC ID No: 45. These molecules include a heavy sec ID number of 44 and a light sec number of 46 If the rest of the lysine c-sec terminal number of 44 is not present. Except for a pharmaceutical composerSE REFIERE A MOLECULAS DE UNION A 4-1BB QUE SON ANTICUERPOS IgG2 Y QUE COMPRENDEN: A) H-CDR1 DE SEC ID NO: 29, B) H-CDR2 DE SEC ID NO: 30, C) H-CDR3 DE SEC ID NO: 31, D) L-CDR1 DE SEC ID NO: 34, E) L-CDR2 DE SEC ID NO: 35, F) L-CDR3 DE SEC ID NO: 36. DICHAS MOLECULAS PRESENTAN UNA REGION VH DE SEC ID NO: 43 Y UNA REGION VL DE SEC ID NO: 45. DICHAS MOLECULAS COMPRENDEN UNA CADENA PESADA DE SEC ID NO: 44 Y UNA CADENA LIGERA DE SEC ID NO: 46 EN EL CASO DE QUE EL RESTO DE LISINA C-TERMINAL DE SEC ID NO: 44 ESTE AUSENTE. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA.
